In W1 ovarian cancer cells, our lead structurefor dual Sirt2/HDAC6 inhibition evoked enhanced effects on cell viabilitycompared to single or combination treatment with the unconjugatedSirt2 and HDAC6 inhibitors. Here, SIRT2 is linked to ovarian cancer.